

Program

[Last updated: October 8, 2024]

Tuesday, December 10 (All times are in CST)

12:00 – 1:30 pm Prevention Special Session: Mechanisms of Obesity Related Risk for Breast Cancer and Approaches to Risk Reduction Moderator: Carol Fabian, University of Kansas Medical Center, Westwood, Kansas

- Lifestyle, Genetic, and Epigenetic Interactions in Predicting Development of Obesity and Response to Calorie Restriction and Physical Activity **Catherine Duggan**, the Fred Hutchinson Cancer Center, Seattle, Washington
- Achieving Sufficient Fat loss and Metabolic Improvement to Reduce Cancer Risk: Newer Generation GLP-1n and GIP Receptor Agonists (Nutrient Sensing Hormone (NUSH) - Based Therapeutics Neil Iyengar, Memorial Sloan Kettering Cancer Center
- Impact and Types of Exercise and Pharmacotherapy in Weight Loss
 John Jakicic, University of Kansas Medical Center, Westwood, Kansas
- Panel Discussion

12:00 – 1:45 pm Career Development: Navigating the Road to Success – Early Funding for Research and Beyond

Moderator: Brenda Ernst, Mayo Clinic Comprehensive Cancer Center, Phoenix, Arizona

- Federal Funding Opportunities Oliver Bogler, National Cancer Institute, Bethesda, Maryland
- Foundation Funding Sara Tolaney, Daba-Farber Cancer Institute, Boston, Massachusetts
- Interactions with Industry
 Minetta Liu, Natera, Austin, Texas
- Panel Discussion

12:00 – 1:45 pm Special Session 3: Sex, Drugs, Rock & Roll Moderator: Christine Ambrosone, Roswell Park Comprehensive Cancer Center,

Buffalo, New York

Patient Advocate: Tomika Bryant, King of Prussia, Pennsylvania

• Supplements and Cannabis Heather Greenlee, Fred Hutchinson Cancer Center, Seattle, Washington

SABCS 2024 Program	
	 Sexual Health Don Dizon, Legorreta Cancer Center at Brown University/Lifespan Cancer Institute, Providence, Rhode Island Exercise During Treatment Rikki Cannioto, Roswell Park Comprehensive Cancer Center, Buffalo, New York Alcohol Marilyn Kwan, Kaiser Permanente Northern California, Pleasanton, California Panel Discussion
2:00 – 3:45 pm	Clinical Workshop: Dose Optimization in Breast Medical Oncology
2:00 – 3:45 pm	 Translational Workshop: Cancer Immunology Discovery Approaches into Clinical Trials Moderator: Christine Desmedt, KU Leuven, Leuven, Belgium Multiplex Imaging for Precision Oncology Raza Ali, Cancer Research UK, Cambridge, United Kingdom Single Cell T-Cell Receptors and B-Cell Receptors Diether Lambrechts, Catholic University of Leuven, Leuven, Belgium Spatial Transcriptomics Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium Cancer Immunology Discovery Approaches into Clinical Trials Emanuela Romano, Institut Curie, Paris, France
4:00 – 5:45 pm	 Educational Session 1: Mind the Gap — Breast Cancer in the Young Moderator: Matteo Lambertini, University of Genova - IRCCS Ospedale Policlinico, San Martino, Genoa, Italy Patient Advocate: Na'Diah Smith, Dallas, Texas Biology of Breast Cancer in Young Women Camila Dos Santos, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York Ovarian Suppression: Who, When, Why, and for How Long Prudence Francis, Peter MacCallum Cancer Centre, Melbourne, Australia Survivorship Jennifer Sheng, Johns Hopkins University, Baltimore, Maryland
4:00 – 5:45 pm	 Educational Session 2: Liquid Biopsy: MRD, CT DNA, and Monitoring Response to Treatment Moderator: Adrian Lee, University of Pittsburgh, Pittsburgh, Pennsylvania Patient Advocate: Ellen Landsberger, New York City, New York Review of Current Technologies Heather Parsons, Dana-Farber Cancer Institute, Boston, Massachusetts Early Detection and Molecular Recurrent Disease Ben Park, Vanderbilt University Medical Center, Nashville, Tennessee Utility in the Metastatic Setting

David Cescon, UHN Princess Margaret Cancer Centre, Toronto, Can	ada
---	-----

• Panel Discussion

4:00 – 5:45 pmEducational Session 3: Tumor Heterogeneity and EvolutionModerator: Reuben S. Harris, UT Health San Antonio, San Antonio, Texas

- Therapy Induced Evolution Nicholas Navin, UT MD Anderson Cancer Center, Houston, Texas
- Genomic and Microenvironment Determinants of Breast Cancer Progression

Christina Curtis, Stanford University, Stanford, California

- Single Cell Genomics in Triple Negative Breast Cancer Ashley Laughney, Weill Cornell Medicine, New York, New York
- Panel Discussion

4:00 – 5:45 pm Educational Session 4: Optimizing Early HER2 Positive Breast Cancer Treatment

Moderator: Javier Cortes, International Breast Cancer Center, Barcelona, Spain Patient Advocate: Thelma Brown, Birmingham, Alabama

- Neoadjuvant Management and Adaptive Strategies
 Gabe Sonke, Netherlands Cancer Institute, Amsterdam, Netherlands
- Treatment of Small Tumors in Early-Stage Setting
 Adrienne Waks, Dana-Farber Cancer Institute, Boston, Massachusetts
- Post Neoadjuvant Management for non pCR
 Joyce O'Shaughnessy, Baylor University, Dallas, Texas
- Panel Discussion
- 5:45 6:15 pm **Refreshment and Networking Break**
- 6:00 7:00 pm Late Breaking Oral Presentations

SABCS 2024 Program

Wednesday, December 11 (All times are in CST)

7:00 – 8:30 am	Concurrent Poster Spotlight Sessions 1-5
8:30 – 8:40 am	Welcome and Opening Remarks
8:40 – 9:20 am	Keynote Address Dr. William Kaelin, Dana-Farber Cancer Institute, Boston, Massachusetts
9:20 – 11:30 am	General Session 1
11:30 am – 12:00 pm	William L. McGuire Memorial Lecture
12:00 – 12:50 pm	Rapid Fire 1
12:00 – 2:00 pm	Poster Session 1 Halls 2-3
12:00 – 1:45 pm	 Early Detection Moderator: Ismail Jatoi, UT Health San Antonio Mays Cancer Center, San Antonio, Texas Risk-Based Screening in the Average Population Karla Kerlikowske, University of California San Francisco, San Francisco, California Novel Imaging Modalities Connie Lehman, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts Screening for High-Risk Women Speaker to be announced Panel Discussion
1:00 – 3:30 pm	Women's Career Development
1:00 – 1:50 pm	 Clinical Case Discussions Moderator: Debra Patt, Texas Oncology, Austin, Texas Patient Advocate: Kelly Shanahan, Tahoe, California Sonya Reid, Vanderbilt Ingram Cancer Center, Nashville, Tennessee Icro Meattini, Florence University Hospital, Florence, Italy Tari King, Dana-Farber Cancer Institute, Boston, Massachusetts Joannie Ivory, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina Anne Salomon, Institut Curie, Paris, France Harold Burstein, Dana-Farber Cancer Institute, Boston, Massachusetts
2:00 – 3:00 pm	State of the Art Session 1: The Winding Road of Immune Biomarkers in Early Breast Cancer Moderator: Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Australia

	 TILs: An Update After 10 Years of Research Roberto Salgado, Peter MacCallum Cancer Centre, Melbourne, Australia Immune Biomarkers Beyond TILs Justin Balko, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee Deploying Immune Biomarkers in Clinical Trials Priyanka Sharma, University of Kansas Medical Center, Westwood, Kansas Panel Discussion
2:00 – 3:00 pm	 Clinical Controversies Omission of Axillary Staging in ER Positive Breast Cancer: Implications on Adjuvant Therapies Moderator: Monica Morrow, Memorial Sloan Kettering Cancer Center, New York, New York Omission of Axillary Staging in ER+ Disease: What is The Data? Elizabeth Mittendorf, Dana-Farber Cancer Institute, Boston, Massachusetts Omission of Axillary Staging in ER+ Disease: Implications for Radiotherapy Speaker to be announced Omission of Axillary Staging in ER+ Disease: Implications for Adjuvant Systemic Therapy Kevin Kalinsky, Emory Winship Cancer Institute, Atlanta, Georgia Radiation Post pCR Richard Zellars, Indiana University School of Medicine, Indianapolis, Indiana Panel Discussion
3:30 – 5:15 pm	 Educational Session 5: Unlocking New Targets with Molecular Degraders Moderator: Carlos Arteaga, UT Southwestern Medical Center, Dallas, Texas PROTACs Lysosome-targeting Chimeras Carolyn Bertozzi, Stanford University, Palo Alto, California Biparatropic Antibodies Panel Discussion
3:30 – 5:15 pm	Educational Session 6: Case Based Clinical Approach to ER Positive Metastatic Breast Cancer Moderator: Sarah Hurvitz, Fred Hutchinson Cancer Center, Seattle, Washington Patient Advocate: Amy Beumer, Mason, Ohio PI3Kinase/AKT Pathway Targeting ESR1 Mutations CDK4/6 Resistance Genomics When to Rebiopsy – Tissue vs Liquid Biopsy Single Agent Hormonal Therapy Sonia Data

• Panel Discussion Michael Oliphant, Harvard Medical School, Boston, Massachusetts

SABCS 2024 Program	
	Aditya Bardia, UCLA David Geffen School of Medicine, Los Angeles, California
	Neil Vasan, Columbia University Irving Medical Center, New York, New York
	Dan Stover, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
3:30 – 5:15 pm	Educational Session 7: The Best of AACR Speakers to be announced
3:30 – 5:15 pm	Educational Session 8: Optimizing Local Therapy
	Moderator: Tari King, Dana-Farber Brigham Cancer Center, Boston,
	Massachusetts
	Patient Advocate: Yvonne Florance, Philadelphia, Pennsylvania
	Let's Talk About PBI Atticking Manager Contact New York, New
	Atif Khan, Memorial Sloan Kettering Cancer Center, New York, New York
	 Axillary Management: When to Dissect and When to Radiate
	Stephanie Wong, Jewish General Hospital Segal Cancer Centre, McGill University Medical School, Montreal, Canada
	 Surgical Prevention and Management of Lymphedema
	Sarah McLaughlin, Mayo Clinic, Jacksonville, Florida
	Panel Discussion
5:30 – 7:00 p.m.	Poster Session 2
	Halls 2-3

6

Thursday, December 12 (All times are in CST)

7:00 – 8:30 am	Concurrent Poster Spotlight Sessions 6-10
8:30 – 9:00 am	 Plenary Lecture The Grand Challenge of Unraveling Social vs Biological Drivers of Racial Disparities in Cancer Outcomes Melissa B. Davis, Morehouse School of Medicine, Atlanta, Georgia
9:00 – 11:45 am	General Session 2
12:00 -2:00 pm	Poster Session 3 Halls 2-3
12:00 – 12:50 pm	Rapid Fire 2
12:30 – 1:45 pm	 The Future of Cancer Genetics Is Here Moderator: Claudine Isaaks, Georgetown University, Washington, DC Patient Advocate: Tanja Spanic, Europa Donna Slovenia, Ljubljana, Slovenia Saturation Genome Editing-Based Functional and Clinical Classification of VUS in BRCA2 Fergus Couch, Mayo Clinic, Rochester, Minnesota Updates on Risk Prediction Models Antonis Antoniou, Cancer Research UK Cambridge Center, Cambridge, United Kingdom Reversion Mutations in BRCA1/2 in Response to Therapy Katherine Nathanson, University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania Panel Discussion
1:00 – 1:50 pm	 Molecular Tumor Board Moderator: Phillipe Afthimos, Insitut Jules Bordet, Brussels, Belgium Jorge Reis-Filho, AstraZeneca, Gaithersburg, Maryland Philippe Bedard, Princess Margaret Cancer Centre, Toronto, Canada Jenna Canzoniero, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, Maryland Bob Riter, Cornell University, Ithaca, New York
2:00 – 3:00 pm	 Translational Controversies Moderator: Antonio Wolff, Johns Hopkins University, Baltimore, Maryland How to Define Triple Negative Breast Cancer Rebecca Dent, National Cancer Center Singapore, Singapore Charles Perou, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina Tumor Agnostic Drug Development Funda Meric, MD Anderson Cancer Center, Houston, Texas Fabrice Andre, Institut Gustave Roussy, Villejuif, France

2:00 – 3:00 pm	State of the Art: Revolutionizing Diagnosis and Discovery with Artificial
	Intelligence

Moderator: Fred Howard, University of Chicago, Chicago, Illinois

- Pathology Speaker to be announced
- Imaging and Screening **Ritse Mann,** Netherlands Cancer Institute, Amsterdam, Netherlands
- Drug Discovery, Deep Learning, and Large Data Management Speaker to be announced
- Panel Discussion

3:30 – 5:15 pm Educational Session 9: Artificial Intelligence in the Clinic

Moderator: **Debra Patt**, Texas Oncology-Austin Central, Austin, Texas Patient Advocate: Kay Firth-Butterfield, Austin, Texas

- Hazards and Opportunities
 Andrew Hantel, Dana-Faber Cancer Institute, Boston, Massachusetts
- Beyond Chat GPT: Generative AI in Healthcare Ian Maurer, Genomoncology, Cleveland, Ohio
- Digital Tools for Clinical Practice
 Emily Ray, UNC Lineberger Comprehensive Cancer Center, Chapel Hill,
 North Carolina
- Panel Discussion

3:30 – 5:15 pmEducational Session 10: ImmunotherapyModerator: Heather McArthur, UT Southwestern Medical Center, Dallas, Texas

- Immunotherapy in Early ER Positive Breast Cancer
 Cesar Santa Maria, John Hopkins Medicine, Baltimore, Maryland
 - Optimization of Treatment in TNBC
 Marleen Kok, Netherlands Cancer Institute, Amsterdam, Netherlands
 - The Future of Immunotherapy Evanthia Roussos Torres, University of Southern California, Los Angeles, California
 - Panel Discussion

3:30 – 5:15 pm Educational Session 11: Mind the Gap — Breast Cancer in Older Adults

Moderator to be announced

Patient Advocate: Sandi Stanford, San Antonio, Texas

- The Aging Immune System with Hormonal Changes Speaker to be announced
- Defining and Avoiding Low Value Surgical Therapy Christina Minami, Brigham and Women's Hospital, New York, New York
- Systemic Therapies
 Hans Wildiers, University Hospital Leuven, Leuven, Belgium
- Panel Discussion

3:30 – 5:15 pm	 Educational Session 12: The Biology and Treatment Implications of Organ Specific Metastases Moderator: Heide Ford, University of Colorado Denver School of Medicine, Denver, Colorado Patient Advocate: Christine Hodgdon, Baltimore, Maryland Brain Metastases Diana Cittelly, University of Colorado Anschutz Medical Campus, Aurora, Colorado Liver Metastases Peter Vermeulen, GZA Hospital Sint-Augustinus, Antwerp, Belgium Bone Metastases Rachelle Johnson, Vanderbilt University Medical Center, Nashville Tennessee
5:30 – 7:00 pm	Poster Session 4
0.00 7.00 pm	Halls 2-3
5:30 – 7:00 pm	Concurrent Poster Spotlight Sessions 16-18
8:00 – 10:30 pm	SABCS Celebration 8:00 – 10:30 p.m.

Texas Ballroom, Grand Hyatt San Antonio Hotel

Friday, December 13 (all times are in CST)

7:00 – 8:30 am	Concurrent Poster Spotlight Sessions 11-15
8:30 – 9:00 am	 Plenary Lecture Cell Atlases as Roadmaps in Cancer Immunology Walid Khaled, University of Cambridge, Cambridge, United Kingdom
9:00 – 11:45 am	General Session 3
12:00 – 12:50 pm	Rapid Fire 3
12:00 -2:00 pm	Poster Session 5 Halls 2-3
12:30 – 2:00 pm	 The Pathologists Conundrum: IHC Testing in Breast Cancer Moderator: David Rimm, Yale School of Medicine, New Haven, Connecticut A Brief History of IHC in Breast Cancer and ASCO CAP Guidelines Speaker to be announced FDA Perspectives on IHC Testing in Breast Cancer Drug Development Reena Philips, FDA, Gaithersburg, Maryland Evaluation of the accuracy of Reading IHC Speaker to be announced
12:30 – 1:45 pm	 New Directions in Breast Cancer Prevention Moderator: Gretchen Benson, National Cancer Institute, Bethesda, Maryland Prevention Vaccines: Where Are We Now and Where Are We Going? Olivera Finn, University of Pittsburgh, Pittsburgh, Pennsylvania Can We Use Biomarkers to Implement Prevention? Seema Khan, Feinberg School of Medicine of Northwestern University, Chicago, Illinois From Bench to Clinical Trial: A New Target for Breast Cancer Prevention Geoff Lindeman, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia Panel Discussion
2:00 – 2:50 pm	 Debate: All Patients Should be Offered Universal Germline Genetic Testing Moderator: Virginia Kaklamani, UT Health San Antonio, San Antonio, Texas Opening Remarks and Polling Debate For Allison Kurian, Stanford University, Stanford, California Debate Against Raymond Kim, UHN Princess Margaret Cancer Centre, Toronto, Canada Closing Remarks and Polling
3:00 – 5:00 pm	Year in Review Moderators: Carlos Arteaga , UT Southwestern Medical Center, Dallas, Texas; an

nd Virginia Kaklamani, UT Health San Antonio, San Antonio, Texas

- Translational Science Updates
 Pedram Razavi, Memorial Sloan Kettering Cancer Center, New York, New
 York
- Early Breast Cancer Updates
 Janice Tsang, University of Hong Kong, Hong Kong
- Advanced Breast Cancer Updates Michael Danso, Virginia Oncology Associates, Norfolk, Virginia Basic Science
- Neil Vasan, Columbia University, New York, New York
- 5:00 5:30 pm Reception Break
- 5:30 7:00 pm View from the Trenches Moderator: Joyce O'Shaughnessy, UT Health San Antonio, San Antonio, Texas